About Alkahest
Alkahest is a Healthcare company based in San Carlos (United States) founded in 2014, and was acquired by Grifols in September 2020. Therapies derived from blood to treat neurological diseases. Alkahest has raised $41 million across 2 funding rounds from investors including Grifols. The company has 82 employees. Its chief executive, as recorded, is Karoly Nikolich. Alkahest offers products and services including AKST4290, AKST/GRF6019/6021, and AKST1210. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Alkahest, Inc.
Company details
Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline. Its research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimers disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Grifols made an investment of 37.5 million for a 45 stake in Alkahest along with another 12.5 million RD and certain commercial rights.
- Headquarters San Carlos, United States
- Employees 82
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website alkahest.com
- Social LinkedIn X
- Acquired by Grifols (Sep 2020)
- Legal Name Alkahest, Inc.
Products & Services of Alkahest
Alkahest offers a comprehensive portfolio of products and services, including AKST4290, AKST/GRF6019/6021, and AKST1210.
Drug candidate for Wet AMD and Parkinson's Disease treatment.
Targets Alzheimer's and Parkinson's with cognitive benefits.
Addresses cognitive impairment in end-stage renal disease.
Funding Insights of Alkahest
Alkahest has successfully raised a total of $41M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $37.5 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41M
- Total Rounds 2
- Last Round Series A — $37.5M
- First Round $3.5M
(Aug 2014)
- Investors Count 1
All 2 funding rounds of Alkahest with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $37.5M | Series A | – | Grifols | – |
| Aug 2014 | $3.5M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Alkahest
Alkahest has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Grifols.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Plasma-derived therapies are developed to treat multiple diseases. | 1909 | grifols.com | Barcelona, Spain |
Investor details for Alkahest
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alkahest
32 people are tracked at Alkahest (10 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 82.
| Name | Role | Group |
|---|---|---|
Karoly Nikolich | Chairman & CEO | Leadership |
Esther Rawner | VP, Clinical Development | Leadership |
Chidam Kumar | Director, Clinical Data Management | Leadership |
Chunmiao Feng | Associate Director Biostatistics, Head Of Analysis | Leadership |
Eliot Obi-Tabot M.D., Sm | Medical Director, Nephrology | Leadership |
Joseph S. McCracken | VP, Business Development | Leadership |
Cesar Cerezo | Chief Medical Officer | Leadership |
Tammy Kent | VP, Human Resources | Leadership |
Sabrina Gu | VP, Regulatory Affairs | Leadership |
Claire Sherman | VP, Clinical Biometrics | Leadership |
Jeffrey L. Cummings | Scientific Advisor | Board & advisors |
Lee Rubin | Scientific Advisor | Board & advisors |
Alfredo Arroyo | Director | Board & advisors |
Eric Reiman | Scientific Advisor | Board & advisors |
Thomas Rando | Scientific Advisor | Board & advisors |
Tomás Dagá Gelabert | Director | Board & advisors |
David Ian Bell | Director | Board & advisors |
Elia Stupka | Scientific Advisor | Board & advisors |
Lennart Mucke | Scientific Advisor | Board & advisors |
Tony Wyss-Coray | Director | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for Alkahest
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alkahest
4 dated milestones of Alkahest across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Alkahest is founded.
- Funding First funding round of $3.5M.
- Funding Latest funding round, Series A, of $37.5M.
- Exit Acquired by Grifols.
Web traffic of Alkahest
The website of Alkahest (alkahest.com) receives about 2.3K visits a month and ranks #5,742,509 among all websites worldwide, #6,226 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▼ 22.7% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,742,509
among all websites
- Category rank#6,226
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit1.6
- Average visit1 min 08 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Alkahest. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
marqaha.com | marqaha.com | 100% | #8,665,445 | – | |
ayurveda.iloveindia.com | ayurveda.iloveindia.com | 98% | – | ||
| grifols.com | 96% | 349.5K | #158,455 | View details | |
alchemianova.com | alchemianova.com | 74% | – | ||
| google.com | 68% | 85.8B | #1 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Alkahest
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Alkahest (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alkahest
Complete news archive for Alkahest
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alkahest
Alkahest was founded in 2014.
Alkahest is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Karoly Nikolich is the CEO of Alkahest, as recorded in our data.
Alkahest is a funded company, having raised a total of $41M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3.5M, raised on Aug 2014.
Alkahest has 82 employees.
Alkahest is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline. Its research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimers disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Grifols made an investment of 37.5 million for a 45 stake in Alkahest along with another 12.5 million RD and certain commercial rights.
Alkahest offers AKST4290, AKST/GRF6019/6021, and AKST1210.
Alkahest has 1 investor. Key investors include Grifols.
Alkahest operates through Alkahest, Inc..
Yes. Alkahest was acquired by Grifols in September 2020.